Inhibition of PARP1 leads to more single-strand breaks in all cells, so why is it a targeted therapy? In healthy cells, DSBs lead to the activation of a repair mechanism referred to as homologous recombination. Since homologous recombination uses an intact DNA strand as a template, this mechanism is accurate and error-free. An important mediator in this pathway is BRCA1. In the absence of BRCA1, DSBs cannot be repaired by homologous recombination, and cells activate an alternative repair pathway termed non-homologous end joining (NHEJ). Intriguingly, NHEJ is highly error-prone. Thus, in BRCA1-deficient cells, the damage executed by PARP inhibitors leads to accumulation of structural DNA lesions, which results in genomic instability and finally apoptotic cell death. Since BRCA2 operates in the same pathway like BRCA1, deficiency of this protein renders the cell vulnerable to PARP inhibitors as well (D’Amours et al.
1999; Tutt and Ashworth
2002). Preclinical in vivo models investigating the effectiveness of PARP inhibitors in the triple-negative/basal-like setting have shown significant tumour regression, longer DFS and OS in mice (Rottenberg et al.
2008). When applying a dose non-cytotoxic for healthy cells in mouse models carrying a
BRCA2 mutation, similar effects were achieved (Kyle et al.
2008; Hay et al.
2009). Recently, several phase I and phase II trials of PARP inhibitors have been performed with
BRCA1 mutation carriers, showing promising anti-tumour activity and only few adverse side effects. For instance, in a phase I trial, the PARP inhibitor olaparib (AZD2281) showed selective activity against
BRCA1/2-mutated breast cancer, whereas BRCA-unrelated tumours remained unaffected (Fong et al.
2009). Based on this finding, Tutt et al. (
2010) demonstrated in a phase II trial on efficacy, safety and tolerability employing solely
BRCA1/2 mutation carriers that olaparib at a higher dose was also associated with an improved objective response rate, while toxicity in
BRCA1/2 mutation carriers was similar low to that reported for patients without BRCA mutations. In a further randomised phase II trial, another PARP inhibitor, BSI-201, showed significantly increased OS in combination with gemcitabine and carboplatin when compared to the standard regimen alone, in heavily pre-treated patients. Importantly, this trial recruited TNBC only and showed in parallel that TNBC also exhibited significantly elevated PARP1 expression levels in contrast to normal breast tissue (O’Shaughnessy et al.
2008). An important question here is that of how to select the right patient population among TNBC subtypes most likely to respond to inhibition of PARP. Addressing this question, several scenarios have recently evolved. As previously mentioned,
BRCA1/2 genotyping may be beneficial, as these tumours affected by mutation show large overlap with the TNBC phenotype. In another study, TNBC were shown to express PARP1 more frequently than other breast cancer subtypes (von Minckwitz et al.
2010). High levels of PARP1 expression also correlated with improved response to chemotherapy, so it is intriguing to see whether levels of PARP1 expression may also predict response to olaparib or BSI-201 in combination with conventional chemotherapy, a trial that is currently being initiated by the respective study group (von Minckwitz et al.
2010). Third, other disruptions of DNA damage repair may also contribute to PARP inhibitor sensitivity. For instance, gene inactivation by promoter methylation of
BRCA1 is a common lesion among sporadic breast tumours (Esteller et al.
2000). Interestingly,
BRCA1-methylated and
BRCA1-mutated breast cancers exhibit similar transcriptional profiles (Hedenfalk et al.
2001). A recent study revealed that the frequency of
BRCA1 methylation is elevated among TNBC, and the inhibition of PARP in
BRCA1-methylated breast cancer cell lines is similar effective as in
BRCA1-mutated cell lines (Veeck et al.
2010), altogether suggesting that also
BRCA1-methylated sporadic breast cancers might be susceptible to PARP inhibitors. In summary, further parameters may become valuable biomarkers of PARP inhibitor response among patients with TNBC. These parameters should be assessed in current and ongoing future trials as stratifying biomarkers of response among TNBC in order to identify the population with the greatest benefit of this kind of treatment. Despite these promising findings, Edwards et al. discovered resistance to PARP inhibitors developing in tumour cells as a result of a deletion in
BRCA2, reactivating the disabled gene (Edwards et al
2008). Besides from using PARP inhibitors as (neo)adjuvant therapy, it has been suggested as a preventive strategy. In patients with an inherited
BRCA1/
2 mutation, preventive use of PARP inhibitors may eliminate any cell developing a second
BRCA1/
2 hit, before it advances further to cancer (Helleday et al.
2005). More research on the long-term effects of PARP inhibitor use needs to be performed before preventive use of PARP inhibitors can be considered.
As described earlier, TNBBC is more likely to express EGFR than other breast cancer subtypes (Nielsen et al.
2004; Cheang et al.
2008; Meche et al.
2009; Collins et al.
2009; Nalwoga et al.
2008). The EGF receptor stimulates cell replication similar to HER2. If targeted, the stimulating effect of EGFR could be diminished, resulting in tumour growth arrest or even tumour regression. EGFR can be targeted by two types of agents, monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors (TKIs). MAbs target the extracellular domain of the receptor, inhibiting its function by blocking ligand binding and receptor internalisation. Possibly, they can also trigger an immune reaction against the EGFR expressing cell. TKIs target the intracellular domain of the receptor, inhibiting its tyrosine kinase activity and rendering the receptor impotent (Harari
2004). Corkery et al. (
2009) evaluated the effect of the TKI gefitinib in combination with docetaxel on TNBC cell lines and found higher effectiveness of the combined therapy scheme. However, as a monotherapy gifitinib seems to be ineffective, since phase II studies showed very little benefit from gifitinib monotherapy in hormone resistant breast tumours (Green et al.
2009; von Minckwitz et al.
2005). Unfortunately, results for another TKI, lapatinib, were as disappointing by showing very little clinical benefit, except for HER2-positive tumours (Burris et al.
2009). Other phase II studies addressing the effectiveness of the monoclonal EGFR antibody cetuximab are currently being performed. It seems that inhibition of EGFR as a monotherapy is ineffective, but it can increase the effectiveness of adjuvant chemotherapy (Oliveras-Ferraros et al.
2008). Cetuximab has already been approved for use in metastatic colon cancer. However, results in breast cancer are not yet convincing for either TKIs or mAbs (Burness et al.
2010); thus, more research is needed to study their potential benefits and improve their effectiveness.